MyLife Technologies developed nanoporous MicroNeedle Arrays (npMNA) for painfree drug delivery via the skin. The nanopores of the MNAs allow for drug storage, such as peptides, small molecules and vaccines. The npMNA devices are made of ceramic material and are combined into a dermal patch.
We completed animal studies with vaccines -including an influenza challenge study- and with an Alzheimer drug (sustained release over multiple days). In Q1 2019, our first-in-human studies with a peptide formulation as a showcase will commence.
The major USPs of npMNA devices are:
• sharp needles of nanoporous, ceramic material
• compatibility with patch technology
• controlled drug release profiles
Pieter Jan Vos (1966) received his MSc in Chemistry from Leiden University, Netherlands, and graduated from ESCP Europe, School of Management, Paris, France. Pieter Jan is former Director New Business Active Pharmaceutical Ingredients at Diosynth / Organon, Oss, the Netherlands. He subsequently founded Amspar, a company that focuses on global licensing of generic pharmaceuticals. Till date, 25 international licensing agreements have been established. Pieter Jan co-founded MyLife Technologies in 2012. He is experienced in innovation and project management in multidisciplinary and multinational teams. Pieter Jan successfully attracted national and European grants and investments from informal investors and regional investor Uniiq.